A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Participants with Metastatic Squamous NSCLC (INTerpath-013)
Phase: Phase II clinical trials
Principal Investigator: Dott.ssa Brambilla Marta
Main Facility: Oncologia Medica 1
Drug: V940
Pathologies: Lung cancer
Randomized 1:1 Phase 2 clinical study evaluating V940 (vaccine) versus placebo in patients with squamous non-small cell lung cancer (NSCLC).**
Last update: 16/07/2026